desvenlafaxine + tamoxifen

Desvenlafaxine + tamoxifen refers to the simultaneous administration of the two drugs—desvenlafaxine and tamoxifen—rather than a single fixed-dose combination product. - **Desvenlafaxine** is a serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant used primarily to treat major depressive disorder as well as to manage hot flashes (vasomotor symptoms) in menopausal women. - **Tamoxifen** is a selective estrogen receptor modulator (SERM) primarily indicated for estrogen receptor-positive breast cancer and for reducing breast cancer recurrence risk. - The combination is clinically relevant in breast cancer survivors taking tamoxifen who experience hot flashes or depressive symptoms—the overlapping adverse effect profile creates demand for safe antidepressant coadministration. - Desvenlafaxine is not a significant inhibitor of CYP2D6 and does not interfere with tamoxifen metabolism to its active metabolite, endoxifen[2][4][6]. - Multiple clinical studies indicate that desvenlafaxine may be a safe and effective choice for vasomotor symptoms or depression in women receiving tamoxifen, not decreasing tamoxifen’s efficacy[1][2][4][6]. - No marketed co-formulated product or trade name exists for this exact drug pair; medical literature and guidelines discuss the drugs' coadministration.

Brand names

NolvadexPristiq

Other names

tamoxifendesvenlafaxine